Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Uterine fibroids: Promising new minimally invasive treatment using high-energy ultrasound waves

There's a new interventional radiology tool showing promise in the treatment of uterine fibroids: magnetic resonance-guided focused ultrasound (MRgFUS), a minimally invasive treatment that uses high-energy ultrasound waves to generate heat at a specific point to destroy uterine fibroid tissue and relieve symptoms.

16 Mar 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

BioSphere Medical reports fourth-quarter and full-year 2009 results

10 Feb 2010

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Elbit Imaging ("Elbit Imaging" "Company") announced today that it intends to restructure its bio-tech and medical holdings (InSightec - 60%, and Gamida Cell - 28%; both on a fully diluted basis) under a wholly-owned Elbit Imaging subsidiary and to offer shares of such subsidiary in a public offering on the Tel Aviv Stock Exchange ("IPO").

2 Feb 2010

Halt Medical commences enrollment in uterine fibroid study

The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.

2 Feb 2010

Japan's MHLW approves InSightec's ExAblate MRgFUS system

InSightec Ltd. announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the company's ExAblate(R) MR-guided Focused Ultrasound (MRgFUS) system for the treatment of women with uterine fibroids.

18 Jan 2010

IntegraMed America plans to open new vein clinic in Columbia, Maryland

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced plans to open a new vein clinic in Columbia, Maryland in mid 2010.

9 Jan 2010

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Montefiore Medical Center recently became the only hospital on the East Coast to conduct the Radio Frequency Ablation procedure to shrink uterine fibroids in women 30 years and older.

6 Jan 2010

Findings suggest abuse is a risk factor for chronic headache

Researchers from the American Headache Society's Women's Issues Section Research Consortium found that incidence of childhood maltreatment, especially emotional abuse and neglect, are prevalent in migraine patients.

5 Jan 2010

BUSM researchers report an inverse association between dairy intake and fibroid risk

Boston University School of Medicine (BUSM) researchers at the Slone Epidemiology Center found that black women with high intake of dairy products have a reduced incidence of uterine leiomyomata (fibroids). This report, based on the Black Women's Health Study, appears in the current issue of the American Journal of Epidemiology.

4 Dec 2009

Royal Philips Electronics highlights its interventional radiology/oncology solutions at the RSNA meeting

On display at this year's Radiological Society of North America (RSNA) annual meeting, Royal Philips Electronics is highlighting its portfolio in the field of interventional radiology/oncology. The company is developing innovative image-guidance technologies for increasing the range and quality of minimally-invasive interventions and therapies.

From Philips Healthcare 1 Dec 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

Cook Medical unveils its uterine manipulator/injectors at 38th Global Congress of Minimally Invasive Gynecology

Laparoscopic surgeons received their first glimpse of Cook Medical’s uterine manipulator/injectors (UMI) last week at the 38th Global Congress of Minimally Invasive Gynecology, sponsored by the American Association of Gynecologic Laparoscopists (AAGL).

23 Nov 2009

Obese patients no more likely to have post-operative complications after robot-assisted laparoscopic myomectomy

Obese patients are no more likely to have post-operative complications than those of average weight when undergoing robotic surgery to remove uterine fibroids, according to a study at Henry Ford Hospital.

20 Nov 2009

Data supports the use of ExAblate as a safe, effective and durable treatment for uterine fibroids

InSightec Ltd. today announced that three new papers published in the November issue of Ultrasound in Obstetrics and Gynecology add to the growing body of data supporting the use of ExAblate(R) as a safe, effective and durable treatment for uterine fibroids.

12 Nov 2009

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

CeloNova BioSciences today announced that the company is submitting to its European Notified Body a request for approval of its new, lime green, 2800 micron size Embozene(TM) Microsphere.

31 Oct 2009

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

BioSphere Medical, Inc. – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

27 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

Uterine artery embolization proves to be better than laparoscopic occlusion of uterine arteries in treating fibroids

BioSphere Medical, Inc. – the pioneer in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy – reports the publication of a study in the October 2009 issue of the Journal of Vascular Interventional Radiology in which the authors conclude that uterine artery embolization (UAE) compares favorably to laparoscopic occlusion of uterine arteries in the treatment of uterine leiomyomas (fibroids) in cases where hysterectomy or myomectomy are not options.

7 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Uterine fibroids: Promising new minimally invasive treatment using high-energy ultrasound waves

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

BioSphere Medical reports fourth-quarter and full-year 2009 results

Elbit Imaging intends to restructure its bio-tech and medical holdings under a subsidiary

Halt Medical commences enrollment in uterine fibroid study

Japan's MHLW approves InSightec's ExAblate MRgFUS system

IntegraMed America plans to open new vein clinic in Columbia, Maryland

Montefiore Medical Center first to perform minimally invasive procedure on uterine fibroids

Findings suggest abuse is a risk factor for chronic headache

BUSM researchers report an inverse association between dairy intake and fibroid risk

Royal Philips Electronics highlights its interventional radiology/oncology solutions at the RSNA meeting

Lysteda tablets to treat menorrhagia approved by the FDA

Cook Medical unveils its uterine manipulator/injectors at 38th Global Congress of Minimally Invasive Gynecology

Obese patients no more likely to have post-operative complications after robot-assisted laparoscopic myomectomy

Data supports the use of ExAblate as a safe, effective and durable treatment for uterine fibroids

CeloNova BioSciences submits a request for approval of its new Embozene Microsphere

BioSphere submits an IDE to the FDA for its QuadraSphere Microsphere product

CeloNova BioSciences' Embozene Microspheres receives approval

Uterine artery embolization proves to be better than laparoscopic occlusion of uterine arteries in treating fibroids

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in